[go: up one dir, main page]

MX2018015118A - Particulas y composiciones de nicotina. - Google Patents

Particulas y composiciones de nicotina.

Info

Publication number
MX2018015118A
MX2018015118A MX2018015118A MX2018015118A MX2018015118A MX 2018015118 A MX2018015118 A MX 2018015118A MX 2018015118 A MX2018015118 A MX 2018015118A MX 2018015118 A MX2018015118 A MX 2018015118A MX 2018015118 A MX2018015118 A MX 2018015118A
Authority
MX
Mexico
Prior art keywords
particles
nicotine
compositions
sugar
composition
Prior art date
Application number
MX2018015118A
Other languages
English (en)
Other versions
MX385972B (es
Inventor
Zuber Gerard
VOLPE Nicolo
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of MX2018015118A publication Critical patent/MX2018015118A/es
Publication of MX385972B publication Critical patent/MX385972B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)

Abstract

La composición se forma de una pluralidad de partículas. Estas partículas incluyen nicotina, un azúcar y un aminoácido o péptido corto.
MX2018015118A 2016-06-30 2017-06-14 Partículas y composiciones de nicotina. MX385972B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177163 2016-06-30
PCT/IB2017/053543 WO2018002756A1 (en) 2016-06-30 2017-06-14 Nicotine particles and compositions

Publications (2)

Publication Number Publication Date
MX2018015118A true MX2018015118A (es) 2019-04-15
MX385972B MX385972B (es) 2025-03-18

Family

ID=56296661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015118A MX385972B (es) 2016-06-30 2017-06-14 Partículas y composiciones de nicotina.

Country Status (17)

Country Link
US (2) US20190133940A1 (es)
EP (1) EP3478264B1 (es)
JP (2) JP2019524648A (es)
KR (1) KR102523677B1 (es)
CN (1) CN109310622A (es)
AR (1) AR108920A1 (es)
AU (1) AU2017286864A1 (es)
CA (1) CA3023630A1 (es)
IL (1) IL263355A (es)
MX (1) MX385972B (es)
PH (1) PH12018502714A1 (es)
RU (1) RU2767064C2 (es)
SG (1) SG11201809594WA (es)
TW (1) TW201801716A (es)
UA (1) UA124535C2 (es)
WO (1) WO2018002756A1 (es)
ZA (1) ZA201806949B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3023630A1 (en) * 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles and compositions
CN112789033A (zh) * 2018-10-02 2021-05-11 学校法人名城大学 吸入粉末剂、其评价方法及其用途
CN120919066A (zh) * 2019-08-30 2025-11-11 伊维股份有限公司 装载的颗粒、其生产方法及其用途
CN110384700A (zh) * 2019-09-03 2019-10-29 云南喜科科技有限公司 一种合成尼古丁的组合物
ES2965397T3 (es) 2019-11-14 2024-04-15 Philip Morris Products Sa Formulación mejorada de polvo seco con sabor a tabaco
EP4076026A1 (en) 2019-12-19 2022-10-26 Juul Labs, Inc. Metal oxide-based gel nicotine compositions
EP4076022A2 (en) 2019-12-19 2022-10-26 Juul Labs, Inc. Organic-based nicotine gel compositions
WO2021201258A1 (ja) * 2020-04-01 2021-10-07 株式会社ＳｔａｔｅＡｒｔ 核酸含有組成物、核酸含有組成物の製造方法及び核酸導入方法
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物
EP4208151B1 (en) * 2020-09-03 2024-07-10 Philip Morris Products S.A. Freeze dried low hygroscopicity active powder compositions
BR112023001929A2 (pt) * 2020-09-03 2023-03-14 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
CN1188111C (zh) * 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
AU783795B2 (en) * 1999-12-30 2005-12-08 Novartis Vaccines And Diagnostics, Inc. Methods for pulmonary delivery of interleukin-2
CN1446077A (zh) * 2000-08-07 2003-10-01 耐科塔医药公司 具有最小聚集的可吸入喷雾干燥4－螺旋束蛋白粉剂
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
CA2583101A1 (en) * 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
FI20060428A7 (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
CN105828819A (zh) * 2014-04-08 2016-08-03 桑萨（巴巴多斯）公司 烟碱制剂及其制备方法
CN106170313B (zh) * 2014-04-28 2020-11-10 菲利普莫里斯生产公司 带香味尼古丁粉末吸入器
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) * 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
CA3023630A1 (en) * 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles and compositions
KR102559152B1 (ko) * 2016-06-30 2023-07-26 필립모리스 프로덕츠 에스.에이. 니코틴 입자
JP2020527377A (ja) * 2017-06-28 2020-09-10 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 吸入器と併用するための粒子を含む容器

Also Published As

Publication number Publication date
AU2017286864A1 (en) 2018-11-15
WO2018002756A1 (en) 2018-01-04
AR108920A1 (es) 2018-10-10
KR102523677B1 (ko) 2023-04-20
RU2018145313A3 (es) 2020-07-30
KR20190025824A (ko) 2019-03-12
ZA201806949B (en) 2019-07-31
EP3478264A1 (en) 2019-05-08
RU2767064C2 (ru) 2022-03-16
BR112018076215A2 (pt) 2019-03-26
TW201801716A (zh) 2018-01-16
SG11201809594WA (en) 2018-11-29
EP3478264B1 (en) 2025-11-19
US20190133940A1 (en) 2019-05-09
IL263355A (en) 2018-12-31
UA124535C2 (uk) 2021-10-05
RU2021132299A (ru) 2021-12-10
JP2022071106A (ja) 2022-05-13
JP2019524648A (ja) 2019-09-05
CN109310622A (zh) 2019-02-05
US20210361567A1 (en) 2021-11-25
CA3023630A1 (en) 2018-01-04
MX385972B (es) 2025-03-18
RU2018145313A (ru) 2020-07-30
PH12018502714A1 (en) 2019-07-29

Similar Documents

Publication Publication Date Title
AR108920A1 (es) Partículas y composiciones de nicotina
CY1122454T1 (el) Στερεες δοσολογικες μορφες palbociclib
EA201992019A1 (ru) Съедобные и биоразлагаемые столовые приборы
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
CA2986942C (en) Anti-tau antibodies and methods of use
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
MX2016010704A (es) Cuchara de excavadora integralmente fundida y metodo de fabricacion de la misma.
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EP3692028A4 (en) INHIBITION OF UBIQUITINE-SPECIFIC PEPTIDASE 30
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EP3413885A4 (en) COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
MX391223B (es) Aislado de proteina de maiz y metodos de manufacturacion del mismo.
LT3860989T (lt) Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
DK3548058T3 (da) Sammensætninger omfattende peptid wkdeagkplvk
MX367669B (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
MX377774B (es) Formulaciones de proteinas.
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
MX393600B (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
EP3328401A4 (en) MOBILE SPERMADOMA WITH PROTEIN 2 AND CANCER
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EP3684191A4 (en) CORN PROTEIN RETENTION DURING EXTRACTION
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201791716A1 (ru) Фармацевтический состав
JO3456B1 (ar) فيروتيوكسيتين بيروجلوتامات
EP3677262A4 (en) KAEMPFEROL ANALOGUE COMPOSITION